Third-generation aromatase inhibitors (AIs)—anastrozole, letrozole, and exemestane—are standard adjuvant endocrine therapy for women with postmenopausal hormone receptor (HR)–positive early-stage breast cancer. The gene discussed is CYP19A1; the disease is breast cancer.